We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Plasma Vitronectin Predicts Response to Fluoropyrimidine-oxaliplatin (FOLFOX) Chemotherapy in Metastatic Colorectal Cancer

Video   Jul 21, 2015

 

Current assessment is based on computed tomography scans, approximately 6-8 weeks after treatment. Earlier molecular predictors of response would be highly beneficial for both patients and clinicians. We have investigated whether useful protein biomarkers could be found in patient plasma, through the use of an advanced MS technique known as SRM-MS. Here, we will discuss the discovery-through-validation pipeline of identifying and validating clinically-relevant biomarkers that can be rapidly translated into the clinic. Briefly, we examined whether the type of blood collection tube would impact on SRM measurement of plasma proteins, in addition to examining the stability of the selected plasma proteome over a 19 week time-course. We then applied SRM to monitor 31 plasma proteins in a trial cohort of advanced CRC patients receiving FOLFOX chemotherapy. Our results indicated that the baseline levels of plasma vitronectin were associated with chemotherapy response, which was successfully validated in a larger patient cohort using SRM and ELISA (n=29 patients). These findings pave the way for further testing in larger cohorts and could lead to more cost-effective and rational uses of systemic chemotherapy.

 
 
 
 

Recommended Videos

What is Leukemia?

Video

Stem cells found in the bone marrow are crucial for our health because they are needed to become new blood cells that sustain and protect our bodies. But when the transformation goes wrong, harmful mutations can cause the cells to start replicating without control -- a type of cancer known as leukemia.

WATCH NOW

HPLC - Normal Phase vs Reverse Phase

Video

Basic info about Normal Phase and Reverse Phase HPLC.

WATCH NOW

Genetic Causes of Myeloma

Video

Myeloma occurs as a result of changes in the genetic material within plasma cells. This animation explains what happens at the genetic level which causes myeloma to develop.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Analysis & Separations Cancer Research Diagnostics Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE